PD-0806 HDR-BT + SBRT for prostate cancer. QoL and toxicity analysis in a prospective phase II trial. (August 2021) - Büchser, D.; Bilbal, A.; Mayrata, E.; Perez, F.; Espinosa, J.M.; Valverde, I.; Santos, B.; Casquero, F.; Gomez- Iturriaga, A.